Vasorum’s Celt ACD Plus Vascular Closure Device Approved by FDA

March 27, 2025—Vasorum USA, Inc. announced FDA approval of the Celt ACD Plus system, which is designed for rapid arterial puncture closure after percutaneous catheter-based vascular procedures.

According to Vasorum USA, the small-bore closure device is available in 5-, 6-, and 7-F sizes.

The next-generation device, which features the company’s blood signal technology, enhances the Celt ACD platform by providing a visual indicator for precise placement and closure. Its mechanism of action reduces major vascular closure complications such as bleeding, hematomas, and pseudoaneurysms, noted the company.

The company stated that the first commercial cases with the Celt ACD Plus device were completed by Joseph Ricotta, MD, at The Prime Vascular Institute in Delray Beach, Florida. Dr. Ricotta is Founder and Program Director of the Vascular Surgery Fellowship at Florida Atlantic University School of Medicine in Boca Raton, Florida.

“The Celt ACD Plus represents a significant advancement in vascular closure,” commented Dr. Ricotta in Vasorum USA’s press release. “By providing a visual indicator for accurate deployment, it shortens the learning curve for new users and expands access to the Celt ACD technology. This is particularly beneficial in settings where ultrasound guidance may not be available, ensuring consistent, reliable closures across a broader range of clinical scenarios.”

Vasorum Ltd. is headquartered in Dublin, Ireland, with operations in the United States.